State of Alaska Department of Revenue Sells Shares of Bruker Co.
January 5, 2024
☀️Trending News
The State of Alaska Department of Revenue recently sold shares of Bruker Corporation ($NASDAQ:BRKR), a leading provider of high-performance scientific instruments and solutions for life science, materials research, and analytical chemistry. The Bruker Corporation has a strong portfolio of innovative products and services, including mass spectrometry, NMR spectroscopy, X-ray diffraction, molecular spectroscopy, analytical instrumentation, and imaging systems.
In addition, they also offer various professional services such as maintenance, training, and applications support. As the market leader in analytical instruments and services, Bruker has a strong presence in a variety of industries including pharmaceuticals, biotechnology, environmental testing, food safety, chemical engineering, and materials sciences. As one of the largest publicly traded companies in the world, Bruker’s stock price has seen considerable growth in recent years. Investment analysts have praised their strategy of investing in R&D to develop new technologies and innovative products. The company has also been recognized for its commitment to corporate responsibility, with sustainability initiatives ranging from energy efficiency to decreasing their carbon footprint. The State of Alaska Department of Revenue’s recent sale of shares of Bruker Corporation is a testament to their confidence in the company’s prospects for long-term growth. With a strong products and services portfolio, continued investment in research and development, and commitment to corporate responsibility, Bruker Corporation is positioned for a bright future.
Earnings
The State of Alaska Department of Revenue recently sold its shares of BRUKER CORPORATION. The company’s earnings report for the third quarter of FY2023, as of September 30 2021, showed that it earned 608.9M USD in total revenue and 87.1M USD in net income. Compared to the same quarter last year, there was a 4.7% decrease in total revenue and 1.1% decrease in net income. However, over the past three years, BRUKER CORPORATION’s total revenue has increased from 608.9M USD to 742.8M USD, demonstrating its consistent growth.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Bruker Corporation. More…
| Total Revenues | Net Income | Net Margin |
| 2.82k | 319.1 | 11.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Bruker Corporation. More…
| Operations | Investing | Financing |
| 316.1 | -438.5 | -169.6 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Bruker Corporation. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 3.82k | 2.57k | 8.36 |
Key Ratios Snapshot
Some of the financial key ratios for Bruker Corporation are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 12.9% | 24.1% | 16.4% |
| FCF Margin | ROE | ROA |
| 7.3% | 23.4% | 7.5% |
Stock Price
On Tuesday, the State of Alaska Department of Revenue announced that it had sold its shares of BRUKER CORPORATION, a leading manufacturer of scientific instruments and solutions. The stock opened at $72.7 and closed at $72.3, indicating a 1.6% decrease from its previous closing price of $73.5. While the exact reasons for the sale are unclear, investors seem to have reacted negatively to the news. Live Quote…
Analysis
GoodWhale conducted an analysis of BRUKER CORPORATION and its fundamentals. We classified the company according to our Star Chart as a ‘gorilla’, which we define as a company which has achieved stable and high revenue or earning growth due to its strong competitive advantage. It is clear from the analysis that BRUKER CORPORATION has a high health score of 8/10 due to its strong cashflows and debt, making it capable to sustain future operations in times of crisis. When it comes to the type of investors that may be interested in BRUKER CORPORATION, it is clear that the company is strong in asset, dividend, growth, and profitability. This makes BRUKER CORPORATION an attractive investment option for both long-term and short-term investors. BRUKER CORPORATION’s strong financials and promising growth potential make it an attractive choice for investors looking for stability and growth. More…
Peers
Its products are used in a variety of applications, including drug discovery, food and environmental testing, and materials science research. The company’s main competitors are Tecan Group AG, Stevanato Group SPA, and Cerus Corporation.
– Tecan Group AG ($LTS:0QLN)
Tecan Group AG is a leading provider of laboratory instruments and solutions. The company has a market cap of 4.56B as of 2022 and a Return on Equity of 6.13%. Tecan provides a wide range of products and services for the life science research, diagnostics and pharmaceutical sectors. The company offers a broad range of solutions for drug discovery, genomics, diagnostics and forensics. Tecan also provides contract research services to the pharmaceutical industry.
– Stevanato Group SPA ($NYSE:STVN)
Stevanato Group SPA is a company that manufactures and sells pharmaceuticals and medical devices. The company has a market cap of 4.89B as of 2022 and a return on equity of 11.0%. The company’s products are sold in over 100 countries and it has a presence in Europe, North America, and Asia.
– Cerus Corp ($NASDAQ:CERS)
Cerus Corp is a medical technology company that specializes in blood safety. The company’s primary product is the Intercept Blood System, which is designed to inactivate viruses, bacteria, parasites, and other potentially harmful agents in donated blood. Cerus Corp’s market cap as of 2022 is 625.13M, and its ROE is -28.3%. The company has been facing some financial difficulties in recent years, but continues to invest in research and development in order to bring new products to market.
Summary
Investing in Bruker Corporation (BRKR) can be a smart choice for investors looking for a strong return. The company is a leader in high-performance scientific instruments and has a presence in the medical, pharmaceutical, and industrial markets. Its products are used to analyze and characterize materials at a molecular level, providing precise data that can be used to make informed decisions. The company has seen a steady upsurge in its stock price over the past five years, with its market capitalization hitting over $10 billion USD.
Bruker’s strong financial position and sizable cash flow have enabled it to make strategic acquisitions to bolster its capabilities and product offerings. The company has had positive operating results in recent years, with revenues continuing to grow. With its diverse product portfolio, strong customer base, and experienced management team, Bruker looks to be well-positioned to continue to deliver strong financial performance in the future.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
